-
Mashup Score: 14
Original Article from The New England Journal of Medicine — Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3ACC 2021: What Could Change UK Cardiology Practice? - 3 year(s) ago
Dr Sukh Nijjer highlights five important studies presented to the American College of Cardiology (ACC) 2021 Scientific Session.
Source: MedscapeCategories: Cardiologists, Latest HeadlinesTweet-
What were your Top 5 studies from #ACC21? How are you going to change your #Cardiology practice? Watch a brief @Medscape @theheartorg overview of #LAAOSIII, #FlowerMI #HOSTExam #PARADISEMI and #RADIANCEHTN. Some clear messages & some caution. https://t.co/vVb1blP8cp
-
-
Mashup Score: 0
Sacubitril/valsartan came suggestively close to showing efficacy for preventing cardiovascular death or heart failure events in patients with acute MI but no history of heart failure.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Safety data from the #PARADISEMI trial presented at #ACC21 provides additional insight about sacubitril/valsartan in #heartfailure patients, a drug they can struggle to access due to #priorauth, Dr. @minnowwalsh comments in @Medscape: https://t.co/8xiBz2DKXq https://t.co/Affx4dWMHv
-
-
Mashup Score: 4ESC Expert Insights at ACC 2021 - 3 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
.@escardio Expert Insights From #PARADISEMI, #FLOWERMI LAAOS III to ATLANTIS, ADAPTABLE, RADIANCE-HTN-TRIO and more, ESC experts bring you key messages from 17 trials & trial updates presented during #ACC21 and the impact of these on clinical practice https://t.co/b5k12KBa4r https://t.co/epKVVnDLiU
-
-
Mashup Score: 1
Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A new video featuring @keaglemd, @DLBHATTMD, and @payalkohlimd reflects on late-breaking science and featured clinical research from day one of #ACC21, including #LAAOS III, #ATLANTIS, #ADAPTABLE, EXPLORER-HCM, and #PARADISEMI! Watch it now: https://t.co/ySSemjqnYF https://t.co/BnJE33DKG0
-
-
Mashup Score: 3
Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli look back on Day 1 of ACC.201 late-breaking science and featured clinical research, including LAAOS III (0:38), ATLANTIS (4:07), ADAPTABLE (8:02), EXPLORER-HCM (13:25), and PARADISE-MI (16:59). Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD),…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Catch up on the highlights from day 1 of #ACC21! @keaglemd, @DLBHATTMD, and @payalkohlimd look back on late-breaking science and featured clinical research, including #LAAOS III, #ATLANTIS, #ADAPTABLE, EXPLORER-HCM, and #PARADISEMI: https://t.co/szQxgLxLAH https://t.co/KXsO9kD2cV
-
-
Mashup Score: 2
Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
#PARADISEMI, the first large-scale assessment of sacubitril/valsartan in reducing heart failure-associated hospitalizations and death in post-heart attack patients, misses the significant improvement mark. #ACC21 https://t.co/uk28kPwimb
-
-
Mashup Score: 0
Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“The results are encouraging, especially when considering recurrent heart failure events and not just the first heart failure events, but the study is not definitive." #PARADISEMI findings presented at #ACC21: https://t.co/uk28kPwimb
-
-
Mashup Score: 5Science News from ACC.21 - 3 year(s) ago
AHA’s Science News coverage of selected important scientific trials from ACC.21, a virtual conference held May 15-17, 2021.
Source: professional.heart.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#PARADISEMI results #ACC21: Heart Failure drug sacubitril/valsartan does not outperform ACE inhibitor after heart attack Read more about PARADISE-MI here: https://t.co/I4Y43hCYS8
-
-
Mashup Score: 3PARADISE-MI Results - 3 year(s) ago
Investigator Marc Pfeffer, MD, PHD summarizes the results of PARADISE-MI.
Source: YouTubeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Watch more about #PARADISEMI here: https://t.co/ZB626Lv8zJ
-
#PARADISEMI ARNI in Acute Myocardial Infarction out in @NEJM by Prof Marc Pfeffer et al. https://t.co/BTCuQ2m00G @EldrinL @gabrielsteg @OtavioBerwanger @scottdsolomon @MajaCikes @markcpetrie20 @Drroxmehran @DLMann_MD @cbgranger Special congrats @BrighamFellows #DrKarolaJering! https://t.co/uRZyV6mmfC